

From: [Jarvis, Candace](#)
To: [James L'Italien, PhD \(jlitalien@avexis.com\)](#)
Cc: [Nancy Boman](#); [Byrnes, Andrew](#); [Xu, Lei \(CBER\)](#); [Singer, Mike](#)
Subject: BLA 125694/0| AveXis, Inc| Information Request 49 (Please Respond by April 16, 2019)
Date: Wednesday, April 10, 2019 2:28:00 PM **Attachments:**
[image013.png](#)

Good afternoon Dr. L'Italien,

We have the following request for information regarding BLA 125694/0. Please respond by April 16, 2019

Based on our record, we have received (b) (4) single patient expanded access requests for the use of your product since the BLA submission. Please confirm whether this is consistent with your record. Please generate a table of demographics, including mean age, sex, race (if available), and nusinersen use.

Please confirm receipt.

Regards,

Candace N. Jarvis
Regulatory Project Manager
Center for Biologics Evaluation and Research
Office of Tissues and Advanced Therapies
U.S. Food and Drug Administration
Tel: 240-402-8315
candace.jarvis@fda.hhs.gov



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.